# Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

Study · id `cardio:ct-nct01189890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01189890](<https://clinicaltrials.gov/study/NCT01189890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01189890

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 480 participants.

## Technical summary

Registry record NCT01189890. Randomized; double masking; primary purpose treatment. Start 2010-08-16 (actual); primary completion 2012-10-31 (actual). Results posted on 2013-06-27.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 480 participants (enrolled count; ClinicalTrials.gov record NCT01189890, source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)
- Started: 2010-08-16 (actual) (ClinicalTrials.gov record NCT01189890, source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)
- Primary completion: 2012-10-31 (actual) (ClinicalTrials.gov record NCT01189890, source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)
- Completion: 2012-10-31 (actual) (ClinicalTrials.gov record NCT01189890, source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)
- Results first posted: 2013-06-27 (ClinicalTrials.gov record NCT01189890, source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01189890-2017-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): sitagliptin phosphate
- Intervention (Drug): Glimepiride
- Intervention (Drug): Placebo to Sitagliptin
- Intervention (Drug): Placebo to Glimepiride
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial (`cardio:pubmed-26041585`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4c9b60e6282e7c188b5f82b4f449214d80ec19def9f940e8d7ef807e5eb0ae61
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
